Vaccine adjuvants market projected to reach $5.43 billion by 2032 with increasing demand globally

From GlobeNewswire: 2025-06-29 14:08:00

The Vaccine Adjuvants Market was valued at USD 3.83 billion in 2024, projected to reach USD 5.43 billion by 2032 with a CAGR of 4.47%. The U.S. market was valued at USD 1.25 billion in 2024, capturing 86% of the North America market share. Adjuvants play a crucial role in enhancing vaccine efficacy and response.

With a focus on boosting immune responses, vaccine adjuvants are becoming essential components in both human and veterinary vaccines. The market sees increased collaborations and innovations in lipid-based delivery systems. Major players include CSL Limited, GlaxoSmithKline, and Novavax Inc., driving advancements in vaccine technologies.

Particulate adjuvants dominated the market with a 31% share in 2023, showing superiority in antigen delivery and immune stimulation. The infectious disease market accounted for 67% of the market in 2024, driven by global vaccination programs. The intramuscular route held a 34% revenue share due to reliable immune response.

North America led the market in 2024 with a 40% share, driven by key players and government support. Asia Pacific is the fastest-growing region due to rising healthcare expenditure and demand for affordable vaccines. Recent developments include advancements in RSV vaccines and novel adjuvant systems to enhance vaccine access worldwide.



Read more at GlobeNewswire: Vaccine Adjuvants Market to Reach USD 5.43 Billion by 2032